Latest Soleus Capital Management, L.P. Stock Portfolio

Soleus Capital Management, L.P. Performance:

2024 Q3: 10.12%YTD: 17.24%2023: 9.22%

Performance for 2024 Q3 is 10.12%, and YTD is 17.24%, and 2023 is 9.22%.

About Soleus Capital Management, L.P. and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, Soleus Capital Management, L.P. reported an equity portfolio of $1.3 Billions as of 30 Sep, 2024.

The top stock holdings of Soleus Capital Management, L.P. are IOVA, TGTX, TERN. The fund has invested 6.2% of it's portfolio in IOVANCE BIOTHERAPEUTICS INC and 4.6% of portfolio in TG THERAPEUTICS INC.

The fund managers got completely rid off PENUMBRA INC (PEN), HUMANA INC (HUM) and TEVA PHARMACEUTICAL INDS LTD (TEVA) stocks. They significantly reduced their stock positions in IMMUNOVANT INC (IMVT), GSK PLC and VAXCYTE INC (PCVX). Soleus Capital Management, L.P. opened new stock positions in GRIFOLS S A (GIKLY), QUIDELORTHO CORP (QDEL) and ELI LILLY & CO (LLY). The fund showed a lot of confidence in some stocks as they added substantially to ORTHOFIX MED INC (OFIX), SANOFI and NATERA INC (NTRA).

Soleus Capital Management, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that Soleus Capital Management, L.P. made a return of 10.12% in the last quarter. In trailing 12 months, it's portfolio return was 29.93%.

New Buys

Ticker	$ Bought
grifols s a	40,152,700
quidelortho corp	31,281,600
eli lilly & co	17,098,600
ani pharmaceuticals inc	16,048,500
elevance health inc	15,418,000
longboard pharmaceuticals in	10,607,900
takeda pharmaceutical co ltd	7,110,000
relay therapeutics inc	6,442,800

New stocks bought by Soleus Capital Management, L.P.

Additions

Ticker	% Inc.
orthofix med inc	1,090
sanofi	879
natera inc	730
establishment labs hldgs inc	296
bicycle therapeutics plc	233
adverum biotechnologies inc	95.08
krystal biotech inc	72.21
verastem inc	70.23

Additions to existing portfolio by Soleus Capital Management, L.P.

Reductions

Ticker	% Reduced
immunovant inc	-96.16
gsk plc	-90.96
vaxcyte inc	-85.4
inari med inc	-77.01
viridian therapeutics inc	-72.06
insmed inc	-70.46
enliven therapeutics inc	-68.84
tango therapeutics inc	-67.32

Soleus Capital Management, L.P. reduced stake in above stock

Sold off

Ticker	$ Sold
x4 pharmaceuticals inc	-2,349,580
the beauty health company	-3,081,060
fate therapeutics inc	-2,853,600
cvrx inc	-7,039,300
teva pharmaceutical inds ltd	-9,530,610
avadel pharmaceuticals plc	-7,156,540
hims & hers health inc	-6,723,270
avita medical inc	-2,114,640

Soleus Capital Management, L.P. got rid off the above stocks

Sector Distribution

Soleus Capital Management, L.P. has about 86.3% of it's holdings in Healthcare sector.

Sector	%
Healthcare	86.3
Others	13.7

Market Cap. Distribution

Soleus Capital Management, L.P. has about 9.7% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
SMALL-CAP	35.4
MID-CAP	30
UNALLOCATED	14
MICRO-CAP	10.8
LARGE-CAP	6.5
MEGA-CAP	3.2

Stocks belong to which Index?

About 58.5% of the stocks held by Soleus Capital Management, L.P. either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	55.2
Others	41.5
S&P 500	3.3

Top 5 Winners (%)		%
RIGL	rigel pharmaceuticals inc	90.8 %
AXGN	axogen inc	90.8 %
APLT	applied therapeutics inc	56.0 %
IMUX	immunic inc	48.6 %
BGNE	beigene ltd	47.9 %

Top 5 Winners ($)		$
AXGN	axogen inc	21.7 M
TGTX	tg therapeutics inc	18.9 M
IOVA	iovance biotherapeutics inc	10.1 M
BGNE	beigene ltd	9.4 M
PRAX	praxis precision medicines i	7.8 M

Top 5 Losers (%)		%
ENTA	enanta pharmaceuticals inc	-19.8 %
JSPR	jasper therapeutics inc	-16.5 %
MRUS	merus n v	-15.0 %
IDYA	ideaya biosciences inc	-12.2 %
IOBT	io biotech inc	-10.3 %

Top 5 Losers ($)		$
JSPR	jasper therapeutics inc	-5.0 M
IDYA	ideaya biosciences inc	-4.6 M
MRUS	merus n v	-3.5 M
SRDX	surmodics inc	-2.4 M
ENTA	enanta pharmaceuticals inc	-2.1 M

Soleus Capital Management, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Soleus Capital Management, L.P.

Soleus Capital Management, L.P. has 86 stocks in it's portfolio. About 35.3% of the portfolio is in top 10 stocks. JSPR proved to be the most loss making stock for the portfolio. AXGN was the most profitable stock for Soleus Capital Management, L.P. last quarter.

Last Reported on: 14 Nov, 2024

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
AADI	aadi bioscience inc	0.05	333,227	686,448	unchanged	0.00

ABBV	abbvie inc	0.24	15,750	3,110,310	new

ACLX	arcellx inc	0.60	93,031	7,769,020	reduced	-45.51

ADPT	adaptive biotechnologies cor	0.44	1,112,750	5,697,280	reduced	-35.31

ADVM	adverum biotechnologies inc	0.16	287,246	2,016,470	added	95.08

ALEC	alector inc	0.44	1,207,370	5,626,350	reduced	-46.08

ALNY	alnylam pharmaceuticals inc	1.26	59,400	16,336,800	reduced	-17.15

ANIP	ani pharmaceuticals inc	1.24	269,000	16,048,500	new

APLT	applied therapeutics inc	0.45	680,784	5,786,660	reduced	-46.38

ARVN	arvinas inc	0.44	228,800	5,635,340	new

AXGN	axogen inc	3.26	3,005,940	42,143,300	reduced	-9.07

BCAB	bioatla inc	0.34	2,517,480	4,430,760	reduced	-35.47

BCYC	bicycle therapeutics plc	0.14	78,315	1,772,270	added	233

BDSX	biodesix inc	0.56	4,038,060	7,187,760	reduced	-33.93

BGNE	beigene ltd	1.44	82,750	18,578,200	reduced	-39.91

BHC	bausch health cos inc	0.90	1,424,000	11,619,800	added	18.08

BLCO	bausch plus lomb corp	0.47	312,000	6,018,480	new

CCCC	c4 therapeutics inc	2.92	6,604,000	37,642,800	added	62.98

CELC	celcuity inc	1.44	1,245,390	18,568,700	added	2.82

CSTL	castle biosciences inc	1.46	662,332	18,889,700	reduced	-22.41